Suchergebnisse
Suchergebnisse:
Tasuku Honjo (本庶 佑, Honjo Tasuku, born January 27, 1942) is a Japanese physician-scientist and immunologist. He won the 2018 Nobel Prize in Physiology or Medicine and is best known for his identification of programmed cell death protein 1 (PD-1).
- Molecular Immunology
- Japanese
It was one of the most devastating American bombing raids targeting civilians, which took place in Toyama City on August 1, 1945, just two weeks before the end of the war. We escaped the fire by jumping into a ditch beside a rice field to avoid the heat from the nearby burning houses.
Tasuku Honjo. The Nobel Prize in Physiology or Medicine 2018. Born: 27 January 1942, Kyoto, Japan. Affiliation at the time of the award: Kyoto University, Kyoto, Japan. Prize motivation: “for their discovery of cancer therapy by inhibition of negative immune regulation”. Prize share: 1/2.
1. Okt. 2018 · In 1992, a few years before Allison’s discovery, Tasuku Honjo discovered PD-1, another protein expressed on the surface of T-cells. Determined to unravel its role, he meticulously explored its function in a series of elegant experiments performed over many years in his laboratory at Kyoto University. The results showed that PD-1 ...
9. Mai 2024 · Tasuku Honjo (born January 27, 1942, Kyoto, Japan) is a Japanese immunologist who contributed to the discovery of mechanisms and proteins critical to the regulation of immune responses and whose work led to the development of novel immunotherapies against cancer.
- Kara Rogers
1. Okt. 2018 · Tasuku Honjo and James Allison share the 2018 Nobel Prize in Physiology or Medicine for discovering how to unleash the immune system to attack cancer cells. They studied different proteins that act as brakes on T cells, leading to the development of drugs that have extended survival in some patients.
Tasuku Honjo is a distinguished professor and deputy director-general of KUIAS, and a Nobel laureate in medicine for his discovery of PD-1. He has also made significant contributions to molecular immunology, class switch recombination, and cancer immunotherapy.
